Eaton Vance Management Neurocrine Biosciences Inc Transaction History

Eaton Vance Management

$67.5 Billion
Q3 2022

A detailed history of Eaton Vance Management transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Eaton Vance Management holds 1,347,820 shares of NBIX stock, worth $200 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares

1,347,820

Previous 1,469,617 8.29%

Holding current value

$200 Million

Previous $143 Million 0.07%

% of portfolio

0.21%

Previous 0.2%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $11.2 Million - $13.1 Million	-121,797 Reduced 8.29%	1,347,820 $143 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $1.03 Million - $1.36 Million	13,569 Added 0.93%	1,469,617 $143 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $28.3 Million - $37.1 Million	-390,867 Reduced 21.16%	1,456,048 $137 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $3.11 Million - $4.14 Million	-38,991 Reduced 2.07%	1,846,915 $157 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $56.3 Million - $64.6 Million	652,772 Added 52.94%	1,885,906 $181 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $37.3 Million - $42.6 Million	416,718 Added 51.04%	1,233,134 $120 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $25.2 Million - $34.4 Million	287,927 Added 54.48%	816,416 $79.4 Million
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $34.7 Million - $43.3 Million	399,834 Added 310.78%	528,489 $50.7 Million
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $798,719 - $1.21 Million	10,634 Added 9.01%	128,655 $11.1 Million
Q4 2019 Feb 11, 2020	SELL	$86.8 - $118.57 $1.39 Million - $1.9 Million	-16,007 Reduced 11.94%	118,021 $12.7 Million
Q2 2019 Aug 16, 2019	SELL	$72.24 - $91.27 $2.09 Million - $2.64 Million	-28,973 Reduced 17.77%	134,028 $11.3 Million
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $2.33 Million - $3.07 Million	33,567 Added 25.93%	163,001 $14.4 Million
Q4 2018 Feb 07, 2019	BUY	$68.32 - $124.36 $1.52 Million - $2.77 Million	22,280 Added 20.79%	129,434 $9.24 Million
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $2.7 Million - $3.44 Million	27,331 Added 34.24%	107,154 $13.2 Million
Q2 2018 Aug 10, 2018	BUY	$75.3 - $105.99 $1.91 Million - $2.69 Million	25,349 Added 46.53%	79,823 $7.84 Million
Q1 2018 May 07, 2018	BUY	$75.88 - $92.43 $2.62 Million - $3.19 Million	34,474 Added 172.37%	54,474 $4.52 Million
Q4 2017 Feb 12, 2018	BUY	$58.53 - $77.59 $1.17 Million - $1.55 Million	20,000	20,000 $1.55 Million

Others Institutions Holding NBIX

# of Institutions

634

Shares Held

94.1M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.

Account

Eaton Vance Management Neurocrine Biosciences Inc Transaction History